Português 
Español 
简体中文 
Unverified company
Facebook
Whatsapp
Twitter
Linkedin
Description
It is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic Non-small Cell Lung Cancer (NSCLC) whose disease has progressed on
• Crizotinib and at least one other ALK inhibitor for metastatic disease; or
• Alectinib as the first ALK inhibitor therapy for metastatic disease; or
• Ceritinib as the first ALK inhibitor therapy for metastatic disease
- Lorlatinib
- NSCLC
- cancer
- ALK
- lorbrena
Production Capacity:
Not informed
Delivery Timeframe:
Not informed
Incoterms:
DES - Delivered Ex Ship
Packaging Details:
Not informed
More about
dawn pharmaceutical
1000-5000
Employees
100K - 200K
Sales volume (USD)
30%
% Export sales
1974
Year
Established
Business type
- Industry / Manufacturer
- Distributor / Wholesaler
Keywords
- medicine
- drug
Contact and location
-
king lingkonglong
-
+880 xxxxxxxx
-
dhaka / uttora | Bangladesh
king lingkonglong
+880 xxxxxxxx
